AstraZeneca PLC (LON:AZN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of AstraZeneca PLC (LON:AZN) have been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is £101.62 ($131.94).

AZN has been the topic of a number of recent analyst reports. Berenberg Bank restated a “buy” rating and issued a £150 ($194.75) price target on shares of AstraZeneca in a research report on Monday, September 2nd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Monday, September 16th. Jefferies Financial Group increased their target price on shares of AstraZeneca from GBX 71 ($0.92) to GBX 74 ($0.96) and gave the stock a “hold” rating in a research note on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a £110 ($142.82) price target on shares of AstraZeneca in a report on Tuesday, September 3rd. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Thursday, July 25th.

AstraZeneca Stock Down 0.1 %

AZN stock opened at £119.30 ($154.89) on Tuesday. AstraZeneca has a 52 week low of GBX 9,461 ($122.84) and a 52 week high of £133.88 ($173.82). The business has a 50-day simple moving average of £123.73 and a 200 day simple moving average of £121.28. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The company has a market cap of £184.92 billion, a PE ratio of 3,787.30, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.

AstraZeneca Cuts Dividend

The business also recently disclosed a dividend, which was paid on Monday, September 9th. Investors of record on Thursday, August 8th were given a dividend of GBX 77.60 ($1.01) per share. The ex-dividend date was Thursday, August 8th. This represents a yield of 0.64%. AstraZeneca’s dividend payout ratio (DPR) is 7,428.57%.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Michel Demare purchased 2,000 shares of the business’s stock in a transaction on Friday, September 13th. The stock was acquired at an average price of GBX 118 ($1.53) per share, for a total transaction of £2,360 ($3,064.14). Company insiders own 0.04% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.